Аграстат

Аграстат (Tirofiban Hydrochloride Monohydrate) is an intravenous antiplatelet medication used to prevent blood clots during high-risk cardiac procedures. This EU-manufactured drug helps maintain blood flow in coronary arteries by inhibiting platelet aggregation. Seek medical guidance for suitability. Short-term use only.

Аграстат is primarily used to reduce the risk of heart attack or stroke in patients undergoing percutaneous coronary intervention (PCI) or those with unstable angina. It works by preventing blood clots from forming in the arteries, particularly in high-risk cardiac scenarios. Patients with recent heart-related events may benefit from its antiplatelet effects. Always consult a healthcare professional to determine if this medication is appropriate.

Аграстат helps maintain blood flow in the coronary arteries by reducing the tendency of blood platelets to clump together. This effect supports the body’s natural circulation during critical cardiac procedures. Patients may experience improved oxygen delivery to the heart muscle as a result. The medication’s action is temporary and closely monitored by medical staff.

Аграстат is administered under strict medical supervision due to its potent effects on blood clotting. Patients with a history of bleeding disorders or recent major surgery should use caution. Regular monitoring of blood parameters is necessary to avoid complications. Inform your healthcare provider about all current medications and medical conditions before use.

Concurrent use of other blood thinners, NSAIDs, or certain antibiotics may increase bleeding risk when taking Аграстат. Herbal supplements like ginkgo biloba or high-dose vitamin E can also heighten this effect. Alcohol and certain pain relievers may interact unpredictably. Always disclose all medications to your doctor to minimize risks.